aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in aTYR PHARMA INC as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +2 vs. Q4 2022
- Shares held
- 34.7M
- +16.9M (+95.5%) vs. Q4 2022
- Total value
- $72.8M
- +$34.0M (+87.5%) vs. Q4 2022
- New holders
- 12
- 13 more added
- Sold out
- 10
- 7 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATYR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 89 | $23.2M |
| Q1 2026 | 111 | $43.7M |
| Q4 2025 | 84 | $42.1M |
| Q3 2025 | 103 | $43.9M |
| Q2 2025 | 110 | $336.5M |
| Q1 2025 | 87 | $186.5M |
| Q4 2024 | 77 | $198.6M |
| Q3 2024 | 56 | $84.3M |
| Q2 2024 | 47 | $75.1M |
| Q1 2024 | 56 | $81.5M |
| Q4 2023 | 46 | $58.1M |
| Q3 2023 | 41 | $58.7M |
| Q2 2023 | 41 | $77.0M |
| Q1 2023 | 37 | $72.8M |
| Q4 2022 | 36 | $40.2M |
| Q3 2022 | 33 | $57.2M |
| Q2 2022 | 36 | $53.1M |
| Q1 2022 | 41 | $105.0M |
| Q4 2021 | 47 | $153.5M |
| Q3 2021 | 42 | $172.1M |
| Q2 2021 | 29 | $33.8M |
| Q1 2021 | 25 | $26.3M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding aTYR PHARMA INC; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 10,189,966 | $21.4M | 0.05% | +4,958,366+94.8% | Added |
| FMR LLC | 7,974,307 | $16.7M | 0.00% | +3,622,900+83.3% | Added |
| Stonepine Capital Management, LLC | 4,825,722 | $10.1M | 3.40% | +4,825,722 | New |
| Alyeska Investment Group, L.P. | 2,473,154 | $5.19M | 0.05% | +1,094,407+79.4% | Added |
| Tikvah Management LLC | 2,460,833 | $5.17M | 2.12% | +1,110,000+82.2% | Added |
| Vanguard Group Inc | 2,094,257 | $4.40M | 0.00% | +954,131+83.7% | Added |
| Samsara BioCapital, LLC | 1,750,000 | $3.67M | 0.76% | +1,750,000 | New |
| CVI Holdings, LLC | 588,571 | $1.24M | 0.47% | +588,571 | New |
| Geode Capital Management, LLC | 578,902 | $1.22M | 0.00% | +336,663+139.0% | Added |
| BlackRock Inc. | 329,177 | $691.3K | 0.00% | +60,231+22.4% | Added |
| Renaissance Technologies LLC | 157,655 | $331.0K | 0.00% | −8,421−5.1% | Reduced |
| Two Sigma Advisers, LP | 153,450 | $322.2K | 0.00% | −2,700−1.7% | Reduced |
| Dimensional Fund Advisors LP | 147,773 | $310.3K | 0.00% | −49,919−25.3% | Reduced |
| JPMorgan Chase & Co | 134,868 | $283.0K | 0.00% | +132,271+5,093.2% | Added |
| Two Sigma Investments, LP | 125,616 | $263.8K | 0.00% | −36,922−22.7% | Reduced |
| Tang Capital Management LLC | 123,430 | $259.2K | 0.04% | 00.0% | Unchanged |
| State Street Corp | 82,908 | $174.1K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 80,000 | $168.0K | 0.00% | +80,000 | New |
| Royal Bank of Canada | 77,073 | $161.0K | 0.00% | +5,305+7.4% | Added |
| Northern Trust Corp | 70,605 | $148.3K | 0.00% | +24,734+53.9% | Added |
| Citadel Advisors LLC | 40,929 | $86.0K | 0.00% | +3,092+8.2% | Added |
| Salem Investment Counselors Inc | 40,000 | $84.0K | 0.00% | +40,000 | New |
| Ensign Peak Advisors, Inc | 37,884 | $79.6K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 35,868 | $75.3K | 0.00% | +35,868 | New |
| Charles Schwab Investment Management Inc | 26,689 | $56.0K | 0.00% | +16,689+166.9% | Added |
| Squarepoint Ops LLC | 12,174 | $25.6K | 0.00% | +12,174 | New |
| D.A. Davidson & Co. | 12,000 | $25.2K | 0.00% | −800−6.3% | Reduced |
| Occudo Quantitative Strategies LP | 11,922 | $25.0K | 0.00% | +11,922 | New |
| Marshall Wace, LLP | 10,947 | $23.0K | 0.00% | −129,349−92.2% | Reduced |
| Tocqueville Asset Management L.P. | 10,150 | $21.3K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2,284 | $4.80K | 0.00% | +2,284 | New |
| Wells Fargo & Company | 1,854 | $3.89K | 0.00% | +159+9.4% | Added |
| Tower Research Capital LLC (TRC) | 1,281 | $3.00K | 0.00% | −16,162−92.7% | Reduced |
| UBS Group AG | 1,000 | $2.10K | 0.00% | +1,000 | New |
| Clearview Wealth Advisors LLC | 500 | $1.05K | 0.00% | +500 | New |
| PFS Partners, LLC | 406 | $853 | 0.00% | 00.0% | Unchanged |
| Raleigh Capital Management Inc. | 13 | $27 | 0.00% | +13 | New |
| VR Adviser, LLC | 0 | $0 | 0.00% | −1,171,436−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −750,000−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −428,460−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −68,106−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −26,419−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −22,685−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −12,214−100.0% | Sold out |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −8,565−100.0% | Sold out |
| RE Dickinson Investment Advisors, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Telemetry Investments, L.L.C. | – | – | – | – | Not filed |